Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 23, 2011

AIDS Drug Assistance Program slams Merck for “unethical behaviour”

The US AIDS Drug Assistance Program has reacted angrily to the news that Merck has refused to lower the price of blockbuster HIV/AIDS drug Isentress, accusing the company of engaging in "unethical behaviour".

The US AIDS Drug Assistance Program has reacted angrily to the news that Merck has refused to lower the price of blockbuster HIV/AIDS drug Isentress, accusing the company of engaging in "unethical behaviour".

Isentress, the generic of which is raltegravir, currently costs over $8,000 per patient per year, making it the most expensive first-line drug.

The news comes hot on the heels of Merck’s announcement that it has agreed to pay a $950m fine to settle criminal and civil charges that it misrepresented the safety of its anti-inflammatory drug Vioxx.

The US Justice Department alleged that Merck promoted the drug for treating rheumatoid arthritis before it had been approved for that indication by the US Food and Drug Administration.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU